Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Bard buys Medivance

You may also be interested in...



Bard’s Summer Pipeline Includes Cooling Arctic Blast Products

Executives recently described a series of upcoming product rollouts, including a new temperature management device.

New Products In Brief

Recent approvals and launches include St. Jude Medical’s EnligHTN renal denervation system for hypertension and Zeltiq Aesthetics’ expanded CoolSculpting clearance for fat reduction.

Bard Buys Lutonix For Lead In Race To U.S. Market With Drug-Coated Balloon

Deal worth up to $325 million makes Bard first in line to enter the U.S. market with a drug-coated balloon. Firm anticipates PMA submission for Moxy in 2014.

Table

View full table

Related Content

Medtech Insight
Medtech Insight

Topics

Tags:
Medical Device
Latest Headlines

Abbott Invests Millions In Clinical Trial Diversification Efforts

Cardio Catch-Up: Two Studies Support Boston Scientific’s Subcutaneous ICD

Cardio Catch-Up: Boston Scientific's Next-Gen Watchman FLX Pro Reduces Thrombi Risk In Trials

Cardio Catch-Up: Boston Scientific's Farapulse PFA Shows Short Learning Curve In European Registry

See All
UsernamePublicRestriction

Register

MT030691

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By